Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 824 Results

Title
Intervention Indication Therapeutic Area Year Actions
Vosoritide for achondroplasia Vosoritide (BMN 111) Achondroplasia Musculoskeletal System 2020 View  |  Download
Voxelotor for Sickle Cell Disease Voxelotor (GBT-440) Sickle cell anaemia Haematology 2017 View  |  Download
Vutrisiran for treating hereditary transthyretin amyloidosis Vutrisiran (ALN-TTRSC02) Amyloidosis Endocrine, nutritional and metabolic disorders 2022 View  |  Download
VX-445/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 12 years and older Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
VX-445/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 years and older Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
VX-659/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 12 years and older Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) , VX-659 (Bamocaftor-potassium) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
VX-659/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 years and older Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) , VX-659 (Bamocaftor-potassium) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Xeomin for sialorrhea in children and adolescents aged 2 to 17 years Botulinum toxin A (Dysport; AbobotulinumtoxinA; Xeomin; Incobotulinumtoxin A; ANT-1207; Botox; OnabotulinumtoxinA; RT002; Daxibotulinumtoxin A; Azzalure; RT-001; NT 201; AGN-151607) Sialorrhea Dental and Oral Health 2020 View  |  Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications